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Predicting Alzheimer Disease via PET Scans
People with the APOE 34 allele are at greater risk of being
diagnosed with Alzheimer disease (AD) than are those
without the allele. In fact, this is themajor genetic risk factor
for AD in the general population. If someone is homozygous
for 34, their risk is even higher, so it is possible to classify
people into three AD risk groups on the basis of their APOE
genotype. Even the homozygous APOE 34 genotype doesn’t
destine someone for dementia, though, and there is nothing
to be done about it anyway, so some people might just ﬁnd
this information nerve-wracking. Reiman et al. want to
ﬁgure out how to better identify the people who are going
to get AD before it actually happens. The point of this is
not to put suchpeople into a ‘‘doomed’’ category but, rather,
toﬁndanendophenotype for AD that canbemonitored and
that could serve as away to test the effects of preventive ther-
apies for AD. Reiman et al. use a PET radioligand that selec-
tively binds to ﬁbrillar aggregates of Ab. These aggregates
are a key neuropathological feature of AD, but we usually
can’t see them until autopsy. They compared PET scans on
cognitively normal individuals from each of the three
APOE 34 genetic-risk groups, and they found that in several
areas of the brain, ﬁbrillar Ab was associated with APOE 34
carrier status. Because the level of genetic risk correlated
with the level of ﬁbrillar Ab seen in the scans, this type of
scan is promising as a way to more closely examine which
individuals might be at risk of getting AD. This is supported
by the ﬁnding that PETscans of peoplewith a probable diag-
nosis of AD generally resulted in higher signals than were
found in cognitively normal individuals and that APOE 34
genotype no longer mattered when people had already pro-
gressed tohaving thedisease.Largerandlongitudinal studies
are going to be a crucial step in determining how well this
type of PET scan will actually predict whether somebody
will get AD, but, if these results do hold true, these scans
could identify those who need a preventive therapy, and it
could aid in the development of that therapy.
Reiman et al. PNAS Early Edition. Published online April 3,
2009. 10.1073/pnas.0900345106.
Regulation of Neuronal Progenitor Proliferation
by DISC1
As its name implies,Disrupted in Schizophrenia 1 (DISC1) was
originally identiﬁed in a single family in which a balanced
translocation led to a high incidence of psychiatric disor-
ders. The gene has since been implicated as a general risk
factor for schizophrenia and other psychiatric disorders.
TheDISC1protein regulatesmultiple steps in neurogenesis,
but the mechanism by which it contributes to a range of
psychiatric disorders has not been clear. Mao et al. provide
multiple lines of evidence that DISC1 regulates the prolifer-
ation of neural progenitor cells in the developing brain and
also in the adult dentate gyrus. Reductions in the level of
DISC1 lead to reductions in neural progenitor proliferation,
because these cells prematurely differentiate into neurons.
This occurs through stabilization of b-catenin, and, in fact,
the effects of DISC1 knockdown can be overcome through
coexpression, in embryonic progenitor cells, of a mutant
form of b-catenin that is resistant to degradation. The
middleman between DISC1 and b-catenin is glycogen syn-
thase kinase 3b (GSK3b). DISC1 interacts with and inhibits
this enzyme, yielding increased stabilization of b-catenin
and downstream activation of its target transcription
factors. Inmice, silencingDISC expression in the adult den-
tate gyrus leads to behaviors that are considered symptoms
of schizophrenia and depression. These behaviors can be
normalized if the mice are injected with a GSK3b inhibitor,
further cementing the importanceof this signalingpathway
in the development of psychiatric disorders.
Mao et al. Cell 136, 1017–1031. 10.1016/j.cell.2008.
12.044.
Enhancer Sequences Govern Cell-Type-Specific
Gene Expression
Not all cis-regulatory elements are easily predicted by
sequence gazing, so it has been tricky to identify some of
these elements on a genome scale. Rather than looking for
sequence motifs, Bing Ren’s lab has been working on ways
to identify these elements via characteristic patterns of
protein binding and histone modiﬁcation. Combining
this knowledge, they now use this information to deter-
mine which elements play a major role in cell-type-speciﬁc
gene expression. They performed chromatin-immunopre-
cipitation-based microarrays (ChIP-chip) on ﬁve human
cell lines to compare patterns of CTCF (insulator-binding
protein) and coactivator p300 binding, as well as to deter-
mine the chromatin signatures at promoters and
enhancers.Whereas there is little variation across cell types
in terms of the chromatin state at promoters and the CTCF
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binding, there are cell-type-speciﬁc histone modiﬁcation
patterns at enhancers that correlate well with cell-type-
speciﬁc gene expression. These experiments suggest that
enhancers are central to setting cell-type-speciﬁc gene
expression patterns. The authors went on to use chromatin
patterns to predict enhancers across the genome in HeLa
cells and compared the results to those from K562 cells.
Most of the enhancers are uniquely predicted in one cell
type or the other, and when some K562-predicted
enhancers were cloned into HeLa cells, the majority of
them were inactive. On the basis of the cell-type speciﬁcity
of enhancers and the number of enhancers predicted from
just these two cell lines, the authors propose that a vast
number of enhancers exists in the human genome.
Heintzman et al. Nature Advance Online Publication.
Published March 18, 2009. 10.1038/nature07829.
Germline Variation Linked to Somatic Mutation
A somatic missense mutation in the JAK2 kinase is found
in the majority of myeloproliferative neoplasms (MPN),
which are characterized by clonal hematopoiesis. There
are three diseases in this group, and they are deﬁned by
the cell lineage that predominates in the expanded popu-
lation. These are: polycythemia vera, essential thrombocy-
topenia, and primary myeloﬁbrosis. Clearly, this single
missense change, JAK2V617F, is not the whole story behind
the development of the MPNs, because the same mutation
is associated with all three diseases and because this
somatic change cannot explain the familial clustering of
the MPNs. This led three groups to explore additional
genetic variation contributing to MPNs. What each of
these groups stumbled upon is the fact that a germline
haplotype block that encompasses part of JAK2 seems to
predispose people to the acquisition of JAK2V617F in cis to
the haplotype. Does the haplotype lead to hypermutability
in some way? Or, does the presence of the JAK2V617F muta-
tion on this particular haplotype background give it a selec-556 The American Journal of Human Genetics 84, 555–556, May 15tive advantage? These questions must be answered in order
for us to unravel the intertwined germline and somatic
contributions to the development of MPN.
Jones et al. Nature Genetics 41, 446–449. 10.1038/ng.334.
Olcaydu et al. Nature Genetics 41, 450–454. 10.1038/
ng.341.
Kilpivaara et al. Nature Genetics 41, 455–459. 10.1038/
ng.342.
The Role of Inflammation and Calcium in DMD
Calcium leakage in muscle cells is a key part of the patho-
logic process in Duchenne muscular dystrophy (DMD).
Bellinger et al. explored this aspect of DMD and found
that inﬂammation contributes to this part of DMD
pathology. Perhaps not surprisingly, they report that
inducible nitric oxide synthase (iNOS), which is made in
inﬂamed tissues, is increased in an age-dependent fashion
in muscle from the mdx mouse model of DMD. What is
surprising is how this kicks off a downward spiral disrupt-
ing calcium homeostasis. The iNOS binds to the ryanodine
receptors RyR1, which are calcium release channels in the
sarcoplasmic reticulum. Ryr1 is nitrosylated by the nitric
oxide produced by iNOS, which in turn depletes the stabi-
lizing protein calstabin-1 from its complex with RyR1.
Without calstabin-1, RyR1 channels are leaky to calcium,
which moves from the sarcoplasmic reticulum into the
cytosol where it activates calpains that produce muscle
damage. Preventing this downward spiral by stabilizing
the Ryr1 channels with a small molecule called S107
improves muscle function and reduces the histological
evidence of muscle damage in mdx mice. The role of
iNOS in DMD pathology is also supported by recent work
by Villalta et al. (Human Molecular Genetics 18:482-496)
who showed that mdx mice that are null mutants for
iNOS exhibit less muscle ﬁber injury.
Bellinger et al. Nature Medicine 15, 325–330. 10.1038/
nm.1916., 2009
